Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

Abuse-Deterrent Opioids: Where Are They Now?

The potential blockbuster category for abuse-deterrent opioids has fizzled. A few stalwarts are pushing on, but the return on investment for many drug manufacturers has been disappointing. Scrip tracked how opioids approved in the last eight years have performed.

Market Access Pricing Strategies Neurology

Roche Gains With Tecentriq IMpower131 NSCLC Data, But For How Long?

Roche is "first to market" with Phase III Tecentriq data in first-line squamous NSCLC setting, but analysts note Merck and Bristol are not far behind.

Analysis Clinical Trials Commercial

Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma

The market for a new FDA-approved indication in frontline classical Hodgkin lymphoma could be worth $650m to $750m, some analysts say.

Approvals Cancer Clinical Trials

 Recent Tweets from Scrip


Commercial Explore this Topic

Set Alert for Commercial

Orsenix Eyes Opportunity For Oral Arsenic Leukemia Therapy

Teva's Trisenox, an IV formulation of arsenic trioxide, was recently approved by the FDA as a first-line treatment for acute promyelocytic leukemia but Incyte founder Kris Vaddi's Orsenix believes its Phase III-ready oral version will take over the market.

Cancer Clinical Trials FDA

Arena Ready For Etrasimod Phase III Face-Off With Celgene's Ozanimod In UC

With significant Phase II results in ulcerative colitis, Arena is planning a Phase III program for its selective S1P receptor modulator etrasimod – a drug that it thinks can best Celgene's S1P-targeting therapy ozanimod on safety and possibly efficacy.

Gastrointestinal Immune Disorders Clinical Trials

TPP Matches Chinese Pharma & Capital With Western Assets

Finding the right partner to enter the Chinese pharma market or access Chinese capital is not a trivial exercise for Western companies. Speaking at the 2018 Biotech Showcase, Tony Chu, founder and managing partner of TPP Healthcare, told Scrip that the advisory company was established to help Western companies achieve their Chinese goals. The sweet spot is late-stage assets for joint venturing or cash thirsty biotechs with programs focused on Asia Pacific health challenges.

Asia Pacific Deals

Merger Buzz Boosts Shares Of India's Troubled Fortis

Shares of Indian hospital chain Fortis Healthcare have risen some 16% in the past month, fuelled by investor hopes of a takeover battle for the financially troubled company. US hedge fund Elliott Management is now said to have entered the fray and be buying up stock.

India Commercial

Alzheon IPO To Fund New Phase III Trialling Of Failed Alzheimer's Drug

Alzheon tells prospective investors it believes beta-amyloid blocker ALZ-801 can succeed in pivotal trials by treating APOE4 subgroup.

Analysis Clinical Trials

AI Drug Developer TwoXAR Raises $10m In Series A

Californian biopharma, TwoXAR, which is using a computational platform to identify drug candidates, de-risks opportunities through preclinical studies, and progresses drug candidates into the clinic, has raised $10m through a series A financing round.

Financing Artificial Intelligence

Arix Says Latest Equity Raising May Be Last For Some Time As Exit Options Loom

Arix Bioscience's £87m equity raising brings to £250m the amount it has raised for incubating life sciences start-ups – but it might be the last for a while if portfolio 'exits' start generating cash, its CEO tells Scrip.

Analysis Business Strategies

Get Ready For The Return Of The Mega-Merger, Leerink Says

Following tax reform, analysts expect imminent biopharma mega-mergers, with Pfizer, Merck and Roche looking to buy, AstraZeneca, Bristol and Vertex looming as take-out candidates, and Amgen as either a buyer or a target.

M & A Business Strategies

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

MIFID II May Hit Small & Midcap EU Biotech Investment

New EU regulation designed to offer greater protection and more transparency for investors could have serious implications for Europe’s small to midcap biotechs just as the European Investment Bank predicts a potential €40bn funding shortfall in key bioclusters by 2021.


Europe Commercial Financing

Exelixis Eyes Liver Cancer OK To Help Drive Cabometyx Sales

Exelixis is looking to get its kidney cancer drug Cabometyx approved for hepatocellular carcinoma as well, but the therapy's long-term success is reliant on combinations with checkpoint inhibitors

Cancer Drug Review

FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

The FDA Commissioner called on payers to take steps to build the US biosimilar market and discouraged some early contracting schemes, calling them pay-for-delay tactics "dressed in the guise of rebates" in a notable speech at AHIP.

Biosimilars Pricing Debate

Theratechnologies Sets $118k Yearly Price For HIV Biologic Trogarzo

The company's monoclonal antibody for multidrug resistant HIV-1 patients licensed from TaiMed will launch soon.

Approvals Pricing Strategies

Research & Development Explore this Topic

Set Alert for Research & Development

Ocugen Heads Toward Phase III In Dry Eye With Potential Benefits Over Older Drugs

Biotech hopes to counter established Restasis and Xiidra in dry eye with a combination of two approved ophthalmology eye drops, offering quicker onset of action, tolerability and strong efficacy.
Clinical Trials Business Strategies Research & Development

PANORAMA Helps Regeneron's Eylea Even Score With Roche's Lucentis

Phase III PANORAMA looks good, so far, for Regeneron's Eylea in diabetic retinopathy without edema.

Ophthalmic Clinical Trials

Cidara To Take Rezafungin Into Phase III In Two Severe Infection Indications

Two-week treatment data comparing the investigational echinocandin antifungal with caspofungin shows trend toward better cure rate with similar efficacy. Cidara plans Phase III trials for treatment and prevention of difficult-to-treat infections.
Research & Development Infectious Diseases

Alzheon IPO To Fund New Phase III Trialling Of Failed Alzheimer's Drug

Alzheon tells prospective investors it believes beta-amyloid blocker ALZ-801 can succeed in pivotal trials by treating APOE4 subgroup.

Analysis Clinical Trials